Login / Signup

FUS-mediated regulation of acetylcholine receptor transcription at neuromuscular junctions is compromised in amyotrophic lateral sclerosis.

Gina PicchiarelliMaria DemestreAmila ZukoMarije BeenJulia HigelinStéphane DieterléMarc-Antoine GoyMoushami MallikChantal SellierJelena Scekic-ZahirovicLi ZhangAngela RosenbohmCéline SijlmansAmr AlySina MersmannInmaculada Sanjuan-RuizAnnemarie HübersNadia MessaddeqMarina WagnerNick van BakelAnne-Laurence BoutillierAlbert LudolphClotilde Lagier-TourenneTobias M BöckersLuc DupuisErik Storkebaum
Published in: Nature neuroscience (2019)
Neuromuscular junction (NMJ) disruption is an early pathogenic event in amyotrophic lateral sclerosis (ALS). Yet, direct links between NMJ pathways and ALS-associated genes such as FUS, whose heterozygous mutations cause aggressive forms of ALS, remain elusive. In a knock-in Fus-ALS mouse model, we identified postsynaptic NMJ defects in newborn homozygous mutants that were attributable to mutant FUS toxicity in skeletal muscle. Adult heterozygous knock-in mice displayed smaller neuromuscular endplates that denervated before motor neuron loss, which is consistent with 'dying-back' neuronopathy. FUS was enriched in subsynaptic myonuclei, and this innervation-dependent enrichment was distorted in FUS-ALS. Mechanistically, FUS collaborates with the ETS transcription factor ERM to stimulate transcription of acetylcholine receptor genes. Co-cultures of induced pluripotent stem cell-derived motor neurons and myotubes from patients with FUS-ALS revealed endplate maturation defects due to intrinsic FUS toxicity in both motor neurons and myotubes. Thus, FUS regulates acetylcholine receptor gene expression in subsynaptic myonuclei, and muscle-intrinsic toxicity of ALS mutant FUS may contribute to dying-back motor neuronopathy.
Keyphrases